Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P0C7U3

UPID:
ZH11B_HUMAN

ALTERNATIVE NAMES:
Zinc finger DHHC domain-containing protein 11B

ALTERNATIVE UPACC:
P0C7U3; A6NHR3

BACKGROUND:
The enzyme Probable palmitoyltransferase ZDHHC11B, alternatively named Zinc finger DHHC domain-containing protein 11B, is implicated in a variety of cellular processes, likely through its action as a palmitoyltransferase. This suggests its role in the post-translational modification of proteins, a critical step for the proper functioning of proteins within the cell.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Probable palmitoyltransferase ZDHHC11B offers a promising avenue for the development of novel therapeutic approaches. Given its probable involvement in cell proliferation, as evidenced by research, targeting this protein could provide new strategies for managing conditions associated with deregulated cell growth.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.